Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH): Aripiprazole Tablets Receives Drug Registration Certificate in the Philippines

Stock News

Sep 12, 2025

Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) announced that its subsidiary Shanghai Shangxiao Zhongxi Pharmaceutical Co., Ltd. has recently received a drug registration certificate from the Philippines Food and Drug Administration for its aripiprazole tablets, granting market approval for the product. Aripiprazole tablets are an antipsychotic medication primarily used for treating schizophrenia and manic episodes associated with bipolar disorder, and can also serve as an adjunctive treatment for depression.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1185939769"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185939769\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185939769?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 15:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185939769","market":"hk","top_or_hot":-1,"title":"Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH): Aripiprazole Tablets Receives Drug Registration Certificate in the Philippines","media":"Stock News","content":"<p>Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) announced that its subsidiary Shanghai Shangxiao Zhongxi Pharmaceutical Co., Ltd. has recently received a drug registration certificate from the Philippines Food and Drug Administration for its aripiprazole tablets, granting market approval for the product. Aripiprazole tablets are an antipsychotic medication primarily used for treating schizophrenia and manic episodes associated with bipolar disorder, and can also serve as an adjunctive treatment for depression.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH): Aripiprazole Tablets Receives Drug Registration Certificate in the Philippines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH): Aripiprazole Tablets Receives Drug Registration Certificate in the Philippines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-12 15:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) announced that its subsidiary Shanghai Shangxiao Zhongxi Pharmaceutical Co., Ltd. has recently received a drug registration certificate from the Philippines Food and Drug Administration for its aripiprazole tablets, granting market approval for the product. Aripiprazole tablets are an antipsychotic medication primarily used for treating schizophrenia and manic episodes associated with bipolar disorder, and can also serve as an adjunctive treatment for depression.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02607","symbol_name":"上海医药","start_time":0,"source_url":"","article_id":"1185939769","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185939769","pubTimestamp":1757663062,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) announced that its subsidiary Shanghai Shangxiao Zhongxi Pharmaceutical Co., Ltd. has recently received a drug registration certificate from the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"601607":"上海医药","02607":"上海医药","BK0188":"融资融券","BK0209":"零售","BK0196":"行业龙头","BK0012":"证金概念","BK0175":"白马股","BK0187":"一线龙头","BK0184":"上海国资改革","BK0097":"医药电商","BK0099":"上海本地重组","BK0028":"国家队","BK1197":"保健护理产品经销商","BK0020":"浦东新区","BK0183":"MSCI概念"},"translate_title":"上海医药控股股份有限公司。（601607.SH）：阿立哌唑片获菲律宾药品注册证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"Shanghai Pharmaceuticals Holding Co.,Ltd. (601607.SH) announced that its subsidiary Shanghai Shangxiao Zhongxi Pharmaceutical Co., Ltd. has recently received a drug registration certificate from the Philippines Food and Drug Administration for its aripiprazole tablets, granting market approval for the product. Aripiprazole tablets are an antipsychotic medication primarily used for treating schizophrenia and manic episodes associated with bipolar disorder, and can also serve as an adjunctive treatment for depression.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}